TTX 181
Alternative Names: AAV9.hCLN2; RGX-181; TTX-181Latest Information Update: 12 Nov 2025
At a glance
- Originator REGENXBIO
- Developer Tern Therapeutics
- Class Gene therapies; Neuroprotectants
- Mechanism of Action Gene transference; Tripeptidyl-peptidase 1 replacements
-
Orphan Drug Status
Yes - Neuronal ceroid lipofuscinosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Neuronal ceroid lipofuscinosis
Most Recent Events
- 08 Oct 2025 Preclinical trials in Neuronal ceroid lipofuscinosis in USA before October 2025 (Intracisternal) (Tern Therapeutics pipeline, October 2025)
- 27 Aug 2024 RGX-181 licensed to Tern Therapeutics worldwide before August 2024
- 13 Nov 2023 RGX 181 is available for licensing as of 09 Nov 2023. https://www.regenxbio.com/therapeutic-programs/